Analysts Offer Predictions for Kodiak Sciences Q3 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD) – Zacks Research raised their Q3 2025 earnings estimates for shares of Kodiak Sciences in a research report issued to clients and investors on Tuesday, October 22nd. Zacks Research analyst R. Department now expects that the company will post earnings of ($1.10) per share for the quarter, up from their previous forecast of ($1.13). The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.52) per share. Zacks Research also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($4.00) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($1.04) EPS and FY2026 earnings at ($3.82) EPS.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.01.

Separately, HC Wainwright restated a “neutral” rating and issued a $3.00 price objective on shares of Kodiak Sciences in a report on Tuesday, September 24th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

Kodiak Sciences Price Performance

NASDAQ:KOD opened at $3.74 on Friday. The firm has a market capitalization of $196.48 million, a price-to-earnings ratio of -0.84 and a beta of 2.34. The company’s 50-day moving average is $2.76 and its two-hundred day moving average is $2.96. Kodiak Sciences has a 1-year low of $1.37 and a 1-year high of $7.77.

Institutional Investors Weigh In On Kodiak Sciences

Several large investors have recently added to or reduced their stakes in KOD. Acadian Asset Management LLC increased its stake in Kodiak Sciences by 14.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,965,449 shares of the company’s stock worth $4,614,000 after buying an additional 242,559 shares during the period. Renaissance Technologies LLC increased its stake in Kodiak Sciences by 21.9% during the 2nd quarter. Renaissance Technologies LLC now owns 708,800 shares of the company’s stock worth $1,666,000 after buying an additional 127,400 shares during the period. Sei Investments Co. purchased a new stake in Kodiak Sciences during the 1st quarter worth approximately $595,000. RIA Advisory Group LLC purchased a new stake in Kodiak Sciences during the 1st quarter worth approximately $489,000. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Kodiak Sciences in the 2nd quarter valued at approximately $207,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.